04:25 PM EDT, 03/15/2024 (MT Newswires) -- OptiNose ( OPTN ) said Friday the US Food and Drug Administration has approved Xhance nasal spray for the treatment of chronic rhinosinusitis without nasal polyps in patients 18 years of age and older.

Xhance combines a a widely used nasal steroid with the Exhalation Delivery System to target inflammation sites, the firm said.